Skip to main content

Neurology · UK

Stem cell treatment for MS - AHSCT, considered honestly.

Autologous haematopoietic stem cell transplant is a high-intensity treatment that can halt relapsing MS in carefully selected patients. It is not a cure, it is not for everyone, and it belongs in a JACIE-accredited unit alongside a specialist neurologist.

See indicative pricing
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Indicative pricing

What a private stem cell treatment for MS costs in the UK.

Indicative ranges across our partner units.

In short

AHSCT for MS in our UK partners: £75,000–£140,000, home 3–4 weeks inpatient.

Procedure Indicative range
AHSCT - cyclophosphamide/ATG conditioning £75,000–£110,000
AHSCT - BEAM conditioning £90,000–£140,000
Neurology MS assessment £350–£650
Haematology consultation £350–£650
3T MRI brain and cervical cord £950–£1,600
Fertility preservation (added) £3,500–£7,500

Prices vary by hospital, by the consultant, by approach, and by whether adjunct services are needed.

The problem

A powerful treatment that needs the right patient - and the right team.

AHSCT is not experimental, but nor is it routine. It works best in early, highly active relapsing MS, and it belongs in accredited units - the referral pathway matters as much as the treatment.

  • Highly active relapsing disease responds best

    Early relapsing-remitting MS with ongoing MRI activity has the strongest evidence. Progressive disease responds much less.

  • DMT ladder matters

    Where a modern high-efficacy DMT has not been tried, we say so. AHSCT is not always the next step.

  • Fertility and vaccination cannot be an afterthought

    Egg or sperm banking before conditioning, and a full re-vaccination schedule from six months are non-negotiable.

When it helps

When stem cell treatment for MS is the right step.

The situations we see most, plus the one red flag that needs urgent attention rather than a routine booking.

  • Highly active relapsing-remitting MS

    Two or more relapses in the last year, or new MRI activity despite a modern DMT.

  • Failed high-efficacy DMT

    Continued activity on natalizumab, ocrelizumab or similar - a strong AHSCT indication in the right patient.

  • Rapidly evolving severe MS at onset

    Aggressive disease at first presentation is an established indication in some centres.

  • Under 55, limited disability

    EDSS around 6.0 or less and limited comorbidity are consistently associated with better outcomes.

  • Intolerable DMT side effects

    Where side effects preclude a high-efficacy DMT, AHSCT can be considered.

  • Neuromyelitis optica (case-by-case)

    Occasionally used in refractory NMO in specialist units. Selection is very careful.

  • Wish for a treatment-free interval

    A well-informed patient choice where continuous DMT is not acceptable long-term.

  • Red flag: progressive MS without relapses

    AHSCT is not currently recommended for pure progressive MS. Alternatives are covered honestly.

Options

Approach and technique both depend on the indication.

What each option involves - the surgical or clinical approach, and how it is tailored to each patient.

  • Cyclophosphamide + ATG conditioning

    Non-myeloablative regimen. Lower toxicity, widely used internationally for MS.

  • BEAM conditioning

    Higher intensity chemotherapy regimen. Used in some UK centres with rigorous selection.

  • Mobilisation and harvest

    Cyclophosphamide plus G-CSF mobilise CD34+ stem cells for apheresis harvest.

  • Selected versus unselected grafts

    Some units select CD34+ cells; most reinfuse the unmanipulated graft.

  • Inpatient care in a JACIE unit

    Positive-pressure rooms, infection surveillance and critical care on site.

  • Fertility preservation

    Egg or sperm banking is offered before conditioning as standard.

  • Re-vaccination schedule

    A structured vaccination programme starts from around six months post-transplant.

  • Long-term surveillance

    Neurology, haematology and infection follow-up for years - never signed off after 12 months.

Safety and recovery

What to expect afterwards - honestly.

A well-established treatment. The things worth planning are the approach, the aftercare and the follow-up.

  • Transplant-related mortality

    Modern UK series report transplant-related mortality of well under 1 percent in selected patients. It is not zero, and we say so clearly.

  • Neutropenic infection

    Serious infection during neutropenia is the biggest short-term risk. Inpatient management in a JACIE unit is why the setting matters.

  • Infertility

    High-dose conditioning can cause infertility. Egg or sperm banking before starting is offered as standard.

  • Secondary autoimmunity

    Thyroid disease and other autoimmune conditions occur in a minority long-term. Surveillance picks them up early.

  • Cardiac and pulmonary strain

    Conditioning is intense. Cardiac and pulmonary work-up is part of pre-transplant assessment for a reason.

  • Vaccination loss

    You lose prior immunity. A structured re-vaccination schedule starts from around six months.

  • Not a cure

    Some patients relapse after AHSCT. It reduces disease activity in most highly active cases but is not a guarantee.

  • Progressive MS response is limited

    AHSCT has little to offer pure progressive MS. Selection is deliberately narrow for a reason.

  • Red flags after transplant

    Fever, breathlessness, new neurological symptoms or bleeding need the same-day transplant team, never a routine call.

Reading your notes

Your notes in four parts. Read the last one first.

Whichever approach was used, the note the consultant sends you keeps to the same shape.

A UK consultant reviewing a patient’s notes

A quiet reminder

Clinical language is precise and can read coldly - we translate it for you.

If you would like us to talk you through the notes before your review, just ask.

  1. 01 Header

    Indication and disease activity

    The neurology summary that supports transplant: relapse count, MRI activity and prior DMT.

  2. 02 Technique

    Conditioning and graft

    The conditioning regimen used, CD34 cell dose reinfused, and any graft manipulation.

  3. 03 Findings

    Engraftment and infections

    Time to neutrophil and platelet engraftment, any infective episodes during the admission.

  4. 04 Impression

    Follow-up and vaccination plan

    Read this first: the follow-up MRI schedule, vaccination programme and shared care arrangements.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

AHSCT is covered by some UK insurers where NHS criteria are met and the unit is JACIE-accredited. Self-funded pathways are common.

Frequently asked

Everything we get asked about stem cell treatment for MS.

Quick answers on suitability, technique, cost and recovery.

  • How much does AHSCT for MS cost privately in the UK?

    Roughly £75,000–£110,000 for a cyclophosphamide/ATG regimen and £90,000–£140,000 for BEAM conditioning. That includes mobilisation, harvest, admission and standard follow-up. Fertility preservation is extra where wanted.

  • Am I a candidate?

    AHSCT works best in highly active relapsing-remitting MS with ongoing activity despite a modern high-efficacy DMT, in patients under about 55 with limited disability. Progressive MS without relapses is not currently an indication.

  • Is AHSCT a cure for MS?

    No. It halts inflammatory disease activity in most well-selected patients and can give years of relapse-free time, but the underlying MS diagnosis remains. Long-term follow-up shows a small proportion relapse.

  • Where should AHSCT for MS be done in the UK?

    Only in a JACIE-accredited transplant unit with critical care on site, and only with a specialist MS neurology team involved from the start. We do not refer anywhere else.

  • What are the risks?

    The biggest short-term risk is infection during neutropenia. Longer term, infertility from conditioning, secondary autoimmunity such as thyroid disease, and vaccination loss are all real. Transplant-related mortality in modern UK series is well under 1 percent in selected patients.

  • What happens to my DMT?

    Most DMTs are stopped before mobilisation. Ocrelizumab, natalizumab and similar are managed on an individual basis. Post-transplant, most patients need no DMT - a small number restart one for relapse.

Related treatments

Looking for something else?